<DOC>
	<DOCNO>NCT00353873</DOCNO>
	<brief_summary>This study compare two treatment strategy ( double dose inhaled steroid add long act beta2 agonist inhale steroid dose ) child control inhaled steroid alone medium dose . The fixed combination SERETIDE 100/50 one inhalation twice daily compare FLIXOTIDE 100 two inhalation twice daily .</brief_summary>
	<brief_title>Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids</brief_title>
	<detailed_description>A multicentre , randomise , double-blind , double dummy , parallel group study compare salmeterol/fluticasone propionate combination ( SERETIDE™ ) dose 50/100mcg twice daily fluticasone propionate ( FLIXOTIDE™ ) dose 200mcg twice daily , deliver via dry powder inhaler ( DISKUS™ ) 12 week asthma child age 4-11 year control inhaled corticosteroid alone medium dose</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : A documented clinical history asthma period least 6 month . A documented history ( within 12 month Visit 1 ) airway reversibility = 15 % base either Forced expiratory volume ( FEV1 ) PEF measure pre post inhalation 200 mcg salbutamol . ( If document history reversibility exists , patient must demonstrate =15 % reversibility Visit 1 ) . Receiving inhaled corticosteroid medium dose ( beclomethasone dipropionate HydroFluoroAlkane ( HFA ) non fine particle = 400500 mcg/day beclomethasone HFA fine particle = 200mcg/day , budesonide =400 mcg/day fluticasone = 200 mcg/day ( fluticasone 250mcg/day subject take 125mcg MDI rather 100mcg Diskus ) , least 3 month prior Visit 1 stable dose least 4 week prior Visit 1 . Able use MiniWright peak flow meter subject parent/guardian able record subject 's maximum PEF correctly . Able perform FEV1 correctly . Subject 's guardian/parent able complete eDRC behalf subject . The eDRC complete guardian/parent . Able use DISKUS™ correctly . At least one parent ( ) /guardian ( ) give write informed consent participate study . At end runin period ( Visit 2 ) , subject must still meet criterion entry runin period also : achieve criterion 'Wellcontrolled ' asthma two 4 week prior Visit 2 . Exclusion criterion : Female subject reach menarche . Received investigational study medication 4 week prior Visit 1 . Experienced respiratory tract infection 4 week prior Visit 1 . Experienced acute asthma exacerbation require emergency room treatment within 4 week hospitalisation within 12 week Visit 1 . Any use oral/parenteral depot corticosteroid within 12 week Visit 1 . Any use longacting inhaled beta2agonists oral beta2agonists within 4 week Visit 1 . Any use leukotriene antagonist theophylline within 4 week Visit 1 . Any known clinical laboratory evidence serious uncontrolled disease ( include serious psychological disorder ) , opinion investigator , likely interfere study . Subjects know suspected hypersensitivity inhale corticosteroid , beta2agonists , component formulation ( e.g . lactose ) A relative site staff , include investigator study cocoordinator . Has previously enter study . Subjects exclude participate treatment period study follow occur runin period : Prebronchodilator FEV1 &lt; 60 % ( assume measurement correctly perform ) . Any change asthma medication ( exclude use prophylactic study specific salbutamol prevention asthma symptom due exercise ) . Respiratory tract infection asthma exacerbation . Use oral , parenteral depot corticosteroid . Emergency visit due asthma . Noncompliance completion eDRC ( i.e . 4 week period visit , non compliance define less 5 day complete data within one week four week subject must complete least 5 day week entire runin period ) .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>FLIXOTIDE</keyword>
	<keyword>asthmatic child 4-11 year</keyword>
	<keyword>SERETIDE</keyword>
	<keyword>asthma-control</keyword>
</DOC>